{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:21:30Z","timestamp":1790749290062,"version":"4.1.0"},"reference-count":83,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Over the past years, positron emission tomography (PET) imaging studies have investigated striatal molecular changes in premanifest and manifest Huntington\u2019s disease (HD) gene expansion carriers (HDGECs), but they have yielded inconsistent results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To systematically examine the evidence of striatal molecular alterations in manifest and premanifest HDGECs as measured by PET imaging studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MEDLINE, ISI Web of Science, Cochrane Library and Scopus databases were searched for articles published until 7 June 2017 that included PET studies in manifest and premanifest HDGECs. Meta-analyses were conducted with random effect models, and heterogeneity was addressed with I<jats:sup>2<\/jats:sup> index, controlling for publication bias and quality of study. The primary outcome was the standardised mean difference (SMD) of PET uptakes in the whole striatum, caudate and putamen in manifest and premanifest HDGECs compared with healthy controls (HCs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-four out of 63 PET studies in premanifest (n=158) and manifest (n=191) HDGECs and HCs (n=333) were included in the meta-analysis. Premanifest and manifest HDGECs showed significant decreases in dopamine D<jats:sub>2<\/jats:sub> receptors in caudate (SMD=\u22121.233, 95% CI \u22121.753 to \u22120.713, p&lt;0.0001; SMD=\u22125.792, 95% CI \u22127.695 to \u22123.890, p&lt;0.0001) and putamen (SMD=\u22121.479, 95% CI \u22121.965 to \u22120.992, p&lt;0.0001; SMD=\u22125.053, 95% CI \u22126.558 to \u22123.549, p&lt;0.0001), in glucose metabolism in caudate (SMD=\u22120.758, 95% CI \u22121.139 to \u22120.376, p&lt;0.0001; SMD=\u22123.738, 95% CI \u22124.880 to \u22122.597, p&lt;0.0001) and putamen (SMD=\u22122.462, 95% CI \u22124.208 to \u22120.717, p=0.006; SMD=\u22121.650, 95% CI \u22122.842 to \u22120.458, p&lt;0.001) and in striatal PDE10A binding (SMD=\u22121.663, 95% CI \u22122.603 to \u22120.723, p=0.001; SMD=\u22122.445, 95% CI \u22123.371 to \u22121.519, p&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PET imaging has the potential to detect striatal molecular changes even at the early premanifest stage of HD, which are relevant to the neuropathological mechanisms underlying the development of the disease.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2017-316633","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T00:10:39Z","timestamp":1505002239000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies"],"prefix":"10.1136","volume":"89","author":[{"given":"Flavia","family":"Niccolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Mrzljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,9]]},"reference":[{"key":"2020050722285266000_89.2.185.1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"The Lancet"},{"key":"2020050722285266000_89.2.185.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70088-7"},{"key":"2020050722285266000_89.2.185.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00241.x"},{"key":"2020050722285266000_89.2.185.4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00259-016-3324-6","article-title":"Current status of PET imaging in Huntington\u2019s disease","volume":"43","author":"Pagano","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020050722285266000_89.2.185.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2020050722285266000_89.2.185.6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"2020050722285266000_89.2.185.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.9.1441"},{"key":"2020050722285266000_89.2.185.8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820020068009"},{"key":"2020050722285266000_89.2.185.9","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1992.00530350075022"},{"key":"2020050722285266000_89.2.185.10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280503"},{"key":"2020050722285266000_89.2.185.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400110"},{"key":"2020050722285266000_89.2.185.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00870669"},{"key":"2020050722285266000_89.2.185.13","first-page":"199","article-title":"Local cerebral glucose utilization in symptomatic and presymptomatic Huntington\u2019s disease","volume":"63","author":"Kuhl","year":"1985","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"key":"2020050722285266000_89.2.185.14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM198702123160701","article-title":"Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington\u2019s disease","volume":"316","author":"Mazziotta","year":"1987","journal-title":"N Engl J Med Overseas Ed"},{"key":"2020050722285266000_89.2.185.15","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1987.00520150010010"},{"key":"2020050722285266000_89.2.185.16","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.9.1553"},{"key":"2020050722285266000_89.2.185.17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/brain\/120.9.1569","article-title":"Cortical control of movement in Huntington\u2019s disease. A PET activation study","volume":"120 (Pt 9)","author":"Weeks","year":"1997","journal-title":"Brain"},{"key":"2020050722285266000_89.2.185.18","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/brain\/122.9.1651","article-title":"Sensory processing in Parkinson\u2019s and Huntington\u2019s disease: investigations with 3D H(2)(15)O-PET","volume":"122 (Pt 9","author":"Boecker","year":"1999","journal-title":"Brain"},{"key":"2020050722285266000_89.2.185.19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn036"},{"key":"2020050722285266000_89.2.185.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.10.015"},{"key":"2020050722285266000_89.2.185.21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0b013e3182478bf2","article-title":"Apparent relative hypermetabolism of selective brain areas in Huntington disease and importance of reference region for analysis","volume":"37","author":"Lee","year":"2012","journal-title":"Clin Nucl Med"},{"key":"2020050722285266000_89.2.185.22","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg119"},{"key":"2020050722285266000_89.2.185.23","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.186"},{"key":"2020050722285266000_89.2.185.24","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.neuropsychologia.2011.05.015","article-title":"The neural substrates of script knowledge deficits as revealed by a PET study in Huntington\u2019s disease","volume":"49","author":"Allain","year":"2011","journal-title":"Neuropsychologia"},{"key":"2020050722285266000_89.2.185.25","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hbm.21134","article-title":"Extrastriatal dopamine D\n                  2\n                receptor binding in Huntington\u2019s disease","volume":"32","author":"Esmaeilzadeh","year":"2011","journal-title":"Hum Brain Mapp"},{"key":"2020050722285266000_89.2.185.26","first-page":"1591","article-title":"Metabolic network abnormalities in early Huntington\u2019s disease: an [(18)F]FDG PET study","volume":"42","author":"Feigin","year":"2001","journal-title":"J Nucl Med"},{"key":"2020050722285266000_89.2.185.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2007.04.001"},{"key":"2020050722285266000_89.2.185.28","unstructured":"Wells G , Shea B , O\u2019Connell D , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: epidemiology\/oxford.asp, 2013. http:\/\/www.ohri.ca\/programs\/clinical"},{"key":"2020050722285266000_89.2.185.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7121.1533"},{"key":"2020050722285266000_89.2.185.30","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2020050722285266000_89.2.185.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2020050722285266000_89.2.185.32","first-page":"15","article-title":"Assessing the influence of a single study in meta-analysis","volume":"47","author":"Tobias","year":"1999","journal-title":"Stata Tech Bull"},{"key":"2020050722285266000_89.2.185.33","unstructured":"Higgins PT , Green S . Cochrane Handbook for Systematic Reviews of Interventions V 5.1.0. The Cochrane collaboration 2011."},{"key":"2020050722285266000_89.2.185.34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410200305"},{"key":"2020050722285266000_89.2.185.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.7.888"},{"key":"2020050722285266000_89.2.185.36","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230603"},{"key":"2020050722285266000_89.2.185.37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/113.5.1405"},{"key":"2020050722285266000_89.2.185.38","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410340114"},{"key":"2020050722285266000_89.2.185.39","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/118.3.689"},{"key":"2020050722285266000_89.2.185.40","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.6.2085"},{"key":"2020050722285266000_89.2.185.41","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","article-title":"Cognitive deficits in Huntington\u2019s disease are predicted by dopaminergic PET markers and brain volumes","volume":"120 (Pt 12)","author":"B\u00e4ckman","year":"1997","journal-title":"Brain"},{"key":"2020050722285266000_89.2.185.42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.3.503"},{"key":"2020050722285266000_89.2.185.43","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.9.1753"},{"key":"2020050722285266000_89.2.185.44","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20564"},{"key":"2020050722285266000_89.2.185.45","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm217"},{"key":"2020050722285266000_89.2.185.46","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn244"},{"key":"2020050722285266000_89.2.185.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02390.x"},{"key":"2020050722285266000_89.2.185.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.077156"},{"key":"2020050722285266000_89.2.185.49","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2114-z"},{"key":"2020050722285266000_89.2.185.50","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2013.9.1.21"},{"key":"2020050722285266000_89.2.185.51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69411"},{"key":"2020050722285266000_89.2.185.52","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","article-title":"Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington\u2019s disease","volume":"41","author":"Matusch","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020050722285266000_89.2.185.53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000037"},{"key":"2020050722285266000_89.2.185.54","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00415-014-7350-7","article-title":"Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington\u2019s disease","volume":"261","author":"Herben-Dekker","year":"2014","journal-title":"J Neurol"},{"key":"2020050722285266000_89.2.185.55","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [\n                  18\u00a0\n               F] MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020050722285266000_89.2.185.56","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv214"},{"key":"2020050722285266000_89.2.185.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2015.08.011"},{"key":"2020050722285266000_89.2.185.58","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm044"},{"key":"2020050722285266000_89.2.185.59","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.21008"},{"key":"2020050722285266000_89.2.185.60","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000222734.56412.17"},{"key":"2020050722285266000_89.2.185.61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.15.5733"},{"key":"2020050722285266000_89.2.185.62","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410310412"},{"key":"2020050722285266000_89.2.185.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2003.11.009"},{"key":"2020050722285266000_89.2.185.64","doi-asserted-by":"crossref","unstructured":"Giamp\u00e0 C , Laurenti D , Anzilotti S , et al . Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. PLoS One 2010;5:e13417.doi:10.1371\/journal.pone.0013417","DOI":"10.1371\/journal.pone.0013417"},{"key":"2020050722285266000_89.2.185.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.02.014"},{"key":"2020050722285266000_89.2.185.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2012.11.016"},{"key":"2020050722285266000_89.2.185.67","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington\u2019s Disease Models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"2020050722285266000_89.2.185.68","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002391"},{"key":"2020050722285266000_89.2.185.69","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntingtons disease progression. PET and clinical observations","volume":"122 (Pt 12)","author":"Andrews","year":"1999","journal-title":"Brain"},{"key":"2020050722285266000_89.2.185.70","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg119"},{"issue":"Suppl 1","key":"2020050722285266000_89.2.185.71","first-page":"S207","article-title":"Imaging of phosphodiesterase 10A (PDE10A) enzyme and D2 receptor levels in the living brain of Huntington\u2019s disease gene expansion carriers and healthy controls (Abstract)","volume":"29","author":"Fitzer-Attas","year":"2014","journal-title":"Mov Disord"},{"key":"2020050722285266000_89.2.185.72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1997.tb01390.x"},{"key":"2020050722285266000_89.2.185.73","first-page":"213","article-title":"Topography of cerebral atrophy in early Huntington\u2019s disease: a voxel based morphometric MRI study","volume":"75","author":"Kassubek","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020050722285266000_89.2.185.74","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25992"},{"key":"2020050722285266000_89.2.185.75","first-page":"196","article-title":"Guidelines for brain radionuclide imaging. Perfusion single photon computed tomography (SPECT) using Tc-99m radiopharmaceuticals and brain metabolism positron emission tomography (PET) using F-18 fluorodeoxyglucose. The Belgian Society for Nuclear Medicine","volume":"101","author":"Vander Borght","year":"2001","journal-title":"Acta Neurol Belg"},{"key":"2020050722285266000_89.2.185.76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00259-001-0701-5","article-title":"Effect of postprandial hyperglycaemia in non-invasive measurement of cerebral metabolic rate of glucose in non-diabetic subjects","volume":"29","author":"Tsuchida","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020050722285266000_89.2.185.77","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.132647"},{"key":"2020050722285266000_89.2.185.78","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1987.84"},{"key":"2020050722285266000_89.2.185.79","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3668"},{"key":"2020050722285266000_89.2.185.80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080178"},{"key":"2020050722285266000_89.2.185.81","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90594-G"},{"key":"2020050722285266000_89.2.185.82","doi-asserted-by":"publisher","DOI":"10.1186\/2191-219X-2-15"},{"key":"2020050722285266000_89.2.185.83","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200312000-00002"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-316633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:08:55Z","timestamp":1601057335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-316633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,9]]},"references-count":83,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,15]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/jnnp-2017-316633"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-316633","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,9]]}}}